Literature DB >> 27837781

Endoscopic Management.

Michael C Bennett1, Ricardo Badillo1, Shelby Sullivan2.   

Abstract

Endoscopic bariatric therapy consists of devices or procedures for primary weight loss or weight regain after Roux-en-Y gastric bypass that are placed or done endoscopically. In most cases, they result in less weight loss, but fewer complications than bariatric surgery; and more weight loss than lifestyle therapy or weight loss medications. These therapies are important advances to treat patients with obesity. This article focuses on therapies or devices with US Food and Drug Administration approval or those with current or planned US pivotal trials.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aspiration therapy; Duodenal-jejunal bypass liner; Endoscopic bariatric therapy; Endoscopic sleeve gastroplasty; Intragastric balloon; Obesity; Primary obesity surgery endoluminal; Transpyloric shuttle

Mesh:

Year:  2016        PMID: 27837781     DOI: 10.1016/j.gtc.2016.07.005

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  5 in total

1.  Advances in endoscopic balloon therapy for weight loss and its limitations.

Authors:  Dinesh Vyas; Kaivalya Deshpande; Yagnik Pandya
Journal:  World J Gastroenterol       Date:  2017-11-28       Impact factor: 5.742

Review 2.  Endoscopic Accessories Used for More Advanced Endoluminal Therapeutic Procedures.

Authors:  Hyunsoo Chung
Journal:  Clin Endosc       Date:  2017-05-31

3.  Ischemic Renal Injury Complicating Intragastric Balloon Insertion.

Authors:  Emad S Aljahdli
Journal:  ACG Case Rep J       Date:  2018-02-28

4.  Experimental Gastric Non-Balloon Devices.

Authors:  Youn I Choi; Kyoung Oh Kim
Journal:  Clin Endosc       Date:  2018-09-27

5.  Latest Developments and Future Perspectives in the Field Of Obesity.

Authors:  Belén Pérez-Pevida; Alexander D Miras
Journal:  Eur Endocrinol       Date:  2017-04-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.